No Data
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Cuts Target Price to $7
Express News | Nuvation Bio Inc. : H.c. Wainwright Cuts Target Price to $7 From $8
Reported Saturday, Nuvation Bio Announces Pooled Data From TRUST-I And TRUST-II Studies, Highlighting Taletrectinib's Best-In-Class Potential For Advanced ROS1-Positive NSCLC
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $5
Jefferies Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $10
Strong Buy Recommendation for Nuvation Bio Based on Superior Clinical Data and Market Valuation